Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases - Summary - MDSpire

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases

  • By

  • Sophia Navarre

  • Maki N. Ishibashi

  • Achuth Nair

  • Ivan Reyes-Torres

  • Meriem Belabed

  • Laszlo Halasz

  • Matthew D. Park

  • Raphaël Mattiuz

  • Merouane Ounadjela

  • Gertrude Gunset

  • Jorge Mansilla-Soto

  • Judith Feucht

  • Annalisa Cabriolu

  • Jessica Le Berichel

  • Alexander Birbrair

  • Justin Eyquem

  • Brian D. Brown

  • Miriam Merad

  • Michel Sadelain

  • Jalal Ahmed

  • May 22, 2026

  • 0 min

Share

Objective:

To investigate how tumor irradiation affects CAR T cell efficacy and persistence in the context of solid tumors.

Key Findings:
  • Irradiation sensitized target+ tumor cells to CAR T cell cytotoxicity.
  • Irradiated tumors showed significantly reduced tumor burden and improved survival in treated mice.
  • Irradiation increased the persistence of CAR T cells in the tumor environment.
Interpretation:

Irradiation enhances the effectiveness of CAR T cell therapy by improving tumor recognition and cytotoxicity.

Limitations:
  • Study primarily focused on a specific lung tumor model, which may not generalize to all solid tumors.
  • Effects of higher radiation doses were not explored beyond 8 Gy.
Conclusion:

Irradiation may serve as a viable strategy to enhance CAR T cell therapy in solid tumors by improving antigen presentation and T cell persistence.

Original Source(s)

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases

  • by Sophia Navarre, Maki N. Ishibashi, Achuth Nair, Ivan Reyes-Torres, Meriem Belabed, Laszlo Halasz, Matthew D. Park, Raphaël Mattiuz, Merouane Ounadjela, Gertrude Gunset, Jorge Mansilla-Soto, Judith Feucht, Annalisa Cabriolu, Jessica Le Berichel, Alexander Birbrair, Justin Eyquem, Brian D. Brown, Miriam Merad, Michel Sadelain, Jalal Ahmed

  • May 22, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer